Blue Jet Healthcare Limited · NSE:BLUEJET
Blue Jet Healthcare — Q4 FY26 Earnings Presentation
42 slides from Blue Jet Healthcare's earnings presentation, May 25, 2026
Slide 1: Stock exchange covering letter
May 25, 2026 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejebhoy Towers “Exchange Plaza” Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai - 400051 Scrip Code (BSE): 544009 Symbol: BLUEJET Sub: Analysts/Investors Presentation on Financial Results for the
Slide 2: Investor Presentation Q4 & FY26
Investor Presentation Q4 & FY26 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table of Content
Table of Content 1 Q4 & FY26 Financials 2 Company at a Glance 3 Contrast Media Intermediates 4 High Intensity Sweeteners 5 Pharma Intermediates & API 6 R&D Capabilities 7 Growth Strategy 8 Management and Board of Directors 3
Slide 5: Q4 & FY26 Financials
‘| Q4 & FY26 Financials Ny @ in roy Pe, Ls I >» gl sing Bi 2 v ‘ uff
Slide 6: Q4 FY26 vs Q3 FY26 (QoQ) Earnings Highlights
Q4 FY26 vs Q3 FY26 (QoQ) Earnings Highlights Financial Highlights ✓ Revenue from Operation in Q4 FY26 is Rs. 2,347 mn, EBITDA Rs. 713 mn (30% Margin) and PAT Rs. 643 mn (27% Margin) ✓ Revenue from Operation in Q3 FY26 was Rs. 1,924 mn, EBITDA Rs. 469 mn (24% Margin) and PAT Rs. 402 mn (21% Margin) ✓
Slide 7: Q4 FY26 vs Q4 FY25 (YoY) Earnings Highlights
Q4 FY26 vs Q4 FY25 (YoY) Earnings Highlights Financial Highlights ✓ Revenue from Operation in Q4 FY26 is Rs.2,347 mn, EBITDA Rs. 713 mn (30% Margin) and PAT Rs. 643 mn (27% Margin) ✓ Revenue from Operation in Q4 FY25 was Rs. 3,404 mn, EBITDA Rs. 1,400 mn (41% Margin) and PAT Rs. 1,101 mn (32% Margin
Slide 8: FY26 Earnings Highlights
FY26 Earnings Highlights Financial Highlights ✓ Revenue from Operation for FY26 is Rs. 9,473 mn, EBITDA Rs. 2,941 mn (31% Margin) and PAT Rs. 2,478 mn (26% Margin) ✓ Revenue from Operation for FY25 was Rs 10,300 mn, EBITDA Rs. 3,777 mn (37% Margin) and PAT Rs. 3,052 mn (30% Margin) ✓ YoY comparison,
Slide 9: FY26 Earnings Highlights: Business Updates
FY26 Earnings Highlights Business Updates ✓ Vizag Project ground-breaking ceremony completed and project activities have commenced ✓ R&D Centre Hyderabad civil construction at Hyderabad commenced – expected to be completed on or before September 2026 – Hiring of Key Resources Initited ✓ Pharma Inter
Slide 10: Q4 FY26 Vs Q4 FY25 Financial Performance – Key Metrics
Q4 FY26 Vs Q4 FY25 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) YoY 23.8% 90.7% -98.8% -90.5% -31.2% Growth: Q4 FY25 Q4 FY26 3,391 2,331 1,928 1,959 1,011 297 368 123 24 12 High-intensity sweetners Contrast media intermediates Pharma intermediates and API Oth
Slide 11: FY26 Vs FY25 Financial Performance – Key Metrics
FY26 Vs FY25 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) YoY -1.5% 22.6% -35.6% -28.4% -8% Growth: FY25 FY26 10,247 9,424 4,039 4,951 4,622 2,978 1,335 1,314 251 180 High-intensity sweetners Contrast media intermediates Pharma intermediates and API Others* T
Slide 12: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs. Mn) Q4 FY26 Q3 FY26 QoQ Q4 FY25 YoY FY26 FY25 YoY Revenue from Operations 2,347 1,924 22.0% 3,404 -31.1% 9,473 10,300 -8.0% Cost Of Goods Sold 1022 928 1,535 4,358 4,612 Gross Profit 1,325 996 33.0% 1,870 -29.2% 5,115 5,688 -10.1% Gross Margin 56.4% 51.7% 5
Slide 13: Financial Performance over the years – Key Metrics
Financial Performance over the years – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) CAGR: 5.9% 7.0% 48.1% 166.8% 13.8% 10,247 9,424 7,185 7,084 6,768 4,778 5,070 4,799 4,951 4,622 4,942 4,039 3,536 2,978 1,575 1,759 1,282 1,335 1,314 987 947 418 412 340 1.33 3 16 55 251 180 High-int
Slide 14: Financials for the last five years
Financials for the last five years Summary Statement of Profit and Loss Summary Statement of Assets and Liabilities Particulars (Rs. Mn) FY21 FY22 FY23 FY24 FY25 FY26 Particulars (Rs. Mn) FY21 FY22 FY23 FY24 FY25 FY26 I. Assets Revenue from Operations 4,989 6,835 7,210 7,116 10,300 9,473 Property, p
Slide 15: Shareholder Information
Shareholder Information Shareholding as on 31st March 2026 Share Information as on 31st March 2026 NSE Ticker BLUEJET Others BSE Ticker 544009 14.8% FII Market Cap (INR Cr) (BSE) 5,676 0.9% DII % free-float 20.2% 4.5% Free-float market cap (INR Cr) 1,146 Cash & Cash Equivalents + Treasury 3,619 Inve
Slide 16: Company at a Glance
. » gf Z 4 Company ata > ata Glance v SS 2
Slide 17: Our Journey
Our Journey • Established Jet Chemicals • Began manufacturing high- • Entered the X-ray contrast Private Limited with Shahad intensity sweeteners - media sector, with a basic facility (Unit I) saccharin and its salts building block (5- NIPA) 1968 1970 2000 • Commenced manufacturing of • Commenced se
Slide 18: Who we are
Who we are A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products with an approach of “Collaboration, Development, Manufacturing” to CDMO business. 17
Slide 19: Blue Jet Healthcare at a glance
Blue Jet Healthcare at a glance 511 1,175.60 KL INR 9,473.2 mn INR 2,940.99 mn Commercialized product reaction capacity across Revenue (FY26) (13.7% EBITDA (FY26) (31.0% portfolio (FY26) 3 facilities (FY26) FY21-26 CAGR) margin) Key metrics INR 3,619 mn 3.75x 24.9% 19.9% Cash and Cash Equivalents +
Slide 20: Overview of our Product Categories
Overview of our Product Categories Contrast Media High Intensity Pharma Intermediates Intermediates Sweeteners & APIs ◼ Contrast media are agents used in medical ◼ High-intensity sweetener business involves ◼ Collaboration with innovator pharmaceutical imaging to enhance the visibility of body tissu
Slide 21: Contrast Media Intermediates
3 Contrast Media Intermediates 20
Slide 22: Overview of Contrast Media and its growth drivers
Overview of Contrast Media and its growth drivers What is contrast media? Types of contrast media ◼ Chemical agents that enhances the contrast of an imaging ◼ X-ray / Computed Tomography (CT) contrast agents: Iodine- modality in diagnostic imaging, thereby aiding diagnosis of based contrast media ag
Slide 23: The global Contrast Media industry is highly concentrated
The global Contrast Media industry is highly concentrated Global Contrast Media Formulation Market Global Medical Imaging Market (USD Bn) Revenue Share of Contrast Agent type, 2024 Revenue (USD Bn) CAGR, 2024-2029F - 6.4% CAGR, 2019-2024: 6.8% 9.5 2% 72.0 8.8 67.7 CAGR, 2024-2029F: 7.2% 8.2 63.6 7.7
Slide 24: High entry barriers for key intermediates’ vendors
High entry barriers for key intermediates’ vendors Characteristics of the Contrast Media Intermediate Blue Jet's positioning Contrast Media market product category performance ✓ More than two decades of experience CAGR: 7.0 % ✓ 75%+ of exports of a selected contrast media Strict internal standards i
Slide 25: Key benefits
Continue to forward integrate into more advanced intermediates for Contrast Media Strong product development and process optimization capabilities underpinned by in-house R&D capabilities Capture larger wallet share with existing customers Focus on molecules with customer interest and strategy in ei
Slide 26: High Intensity Sweeteners
4 High Intensity Sweeteners 25
Slide 27: Blue Jet’s positioning in High Intensity Sweetener
Blue Jet’s positioning in High Intensity Sweetener Blue Jet's positioning High Intensity Sweeteners product category performance Products ◼ Adherence to strict internal standards to ensure consistency in quality, performance, CAGR: 5.9% taste, and impurity profile Revenue (INR mn) ◼ Multiple product
Slide 28: Global High Intensity Sweeteners Market
Global High Intensity Sweeteners Market Global Artificial Sweeetener Market Revenue (USD Mn) Global High-intensity Sweetneer Market, Revenue share by segments, 2024 4,495 3% 3% 4,213 3,948 3,700 Sucralose 3,468 5% 3,250 Aspartame 3,060 9% 2,713 2,882 2,406 2,555 40% Saccharin Stevia 12% Acesulfame K
Slide 29: Pharma Intermediates & API
5Pharma Intermediates & API 28
Slide 30: Trends and features of the Pharma Intermediates and APIs Product Category
Trends and features of the Pharma Intermediates and APIs Product Category Key trends in Pharma Intermediates and CDMO market Revenue and capacity utilization predictability Increased propensity to outsource manufacturing of intermediates & APIs for the CDMO ◼ Enables asset light model and ability to
Slide 31: Overview of Blue Jet’s Pharma Intermediates and APIs Product Category
Overview of Blue Jet’s Pharma Intermediates and APIs Product Category Pharma Intermediate and APIs ◼ Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity product category performance sweetener business ◼ Key focus areas include hi
Slide 32: CDMO Potential in API for Indian Players
CDMO Potential in API for Indian Players Global API CDMO Market by Global CDMO Market by Modality (USD Bn) Global CDMO Market Revenue (USD Bn) Innovation Type (USD Bn) 190.0 CAGR, 2019-2024 - 6.9% 190 CAGR, 2024-2029F - 8.1% 176 135.0 55.0 162 128.8 150 139 93.1 129 68.8 92.1 120 35.7 106 113 67.8 9
Slide 33: Leverage long-standing customer relationships to enter adjacencies in pharma intermediate and API
Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category Focus on three niche areas in providing CDMO services Blue Jet’s positioning Investigational new drugs and new chemical Leverage long-standing relationships with innovator e
Slide 34: R&D Capabilities
6 R&D Capabilities 33
Slide 35: Our R&D framework
Our R&D framework R&D capabilities across Process research Portfolio Process Process scale-up Regulatory filings evaluation development and validation and approvals Analytical research Chemistry research Method Characterization of Polymorphism Pharmaceutical salt High pressure Literature search deve
Slide 36: Sustainability
Sustainability Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint Invested in windmills with installed capacity of 3.3MW Created carbon sinks Focus on enhancing through tree plantations energy efficiency Effluent treatment plants with Minimi
Slide 37: Growth Strategy
ly. 7 Fe Growth Strategy
Slide 38: Our strategies
Our strategies Focus on operational efficiency and mitigation of supply chain risks Continue to forward integrate into Continue to invest in R&D more advanced intermediates for infrastructure and capabilities Contrast Media Leverage our long-standing Build additional production capacity customer rel
Slide 39: Management and Board of Directors
8 Management and Board of Directors 38
Slide 40: Experienced and visionary management team backed by independent Board of Directors
Experienced and visionary management team backed by independent - Board of Directors Management team Akshay Bansarilal Shiven Akshay Naresh Suryakant Shah Ganesh Vimalendu Kumar Singh Chandrashekar Parenky Arora Arora Executive Director, Head Karuppannan (V.K. Singh) President – Research and Executi
Slide 41: Management team and independent board of directors (cont’d)
Experienced and visionary management team backed by independent Board of Directors (cont’d) Management team (cont’d) Independent board of directors Popat B Kedar Sweta Poddar Girish Paman Preeti Gautam Divya Sameer Priyanka Yadav Executive Director Company Secretary and Vanvari Mehta Momaya Independ
Slide 42: Thank you!
Thank you! BLUE JET HEALTHCARE LIMITED INVESTOR RELATIONS AT Registered Office Blue Jet Healthcare Limited 701,702, 7th Floor, Bhumiraj Costarica, Sanjay Sinha, Deputy Chief Financial Officer Sector 18, Sanpada, Navi Mumbai Thane sanjay.sinha@bluejethealthcare.com 400705, Maharashtra, India NSE: BLU